{"name":"Ping-Yen Liu","slug":"ping-yen-liu","ticker":"","exchange":"","domain":"","description":"Ping-Yen Liu is a pharmaceutical company focused on the development and marketing of generic drugs, particularly in the cardiovascular space. The company has two marketed products, Clopidogrel First and Ticagrelor First, which are used for the prevention of atherothrombotic events.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Clopidogrel first","genericName":"Clopidogrel first","slug":"clopidogrel-first","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ticagrelor first","genericName":"Ticagrelor first","slug":"ticagrelor-first","indication":"Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis","status":"marketed"}]}],"pipeline":[{"name":"Clopidogrel first","genericName":"Clopidogrel first","slug":"clopidogrel-first","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ticagrelor first","genericName":"Ticagrelor first","slug":"ticagrelor-first","phase":"marketed","mechanism":"Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation by blocking adenosine diphosphate (ADP) signaling.","indications":["Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis","Chronic coronary disease for secondary prevention of cardiovascular events"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}